Business NewsFeaturedRadical Consumerist

ELEVAI Labs Bolsters Advisory Board With Addition of New Strategic Advisor James R. Headley

Last Updated: 28.1.2024 5:17

James Headley, the Former Head of ZO Skin Health, Will Join the Rapidly Growing Regenerative Skincare Company ELEVAI Labs

ELEVAI Labs, a medical aesthetic biotechnology company specializing in regenerative skincare, proudly announces that cosmetic industry veteran James R. Headley joins the team as a Strategic Advisor.

Mr. Headley, previously CEO of ZO Skin Health, will play an active role in supporting the ELEVAI management team as it evaluates strategic growth initiatives, product launches and partnerships. Headley will also leverage his extensive beauty industry background to support ELEVAI in business development and developing relationships with key opinion leaders in the aesthetic space.

Commenting on the announcement of his joining the ELEVAI advisory board, Headley said:

“I am pleased to join the ELEVAI Labs Team as a Strategic Advisor. I believe that ELEVAI is the most scientifically advanced stem cell exosome technology and medical skincare available for physicians and their patients. Jordan R. Plews, Ph.D., has created the most advanced delivery of mesenchymal stem cell exosomes for post-procedure and patient home maintenance. The positive effects of ELEVAI post-procedure use will change how physicians think about post-procedure treatment, and patients will readily see the benefits of daily home maintenance”.

Source: ELEVAI Labs

???? Kicks Off Coverage of the Emerging and Recession Resilient Cosmeceuticals Industry

Mr. Headley is an experienced pharmaceutical executive and cosmetic industry executive. After beginning his career at F&R Lazarus Department (Federated Department Stores), now Macy’s, he spent nine years at the Estee Lauder Companies. He left to become vice president of sales at Warner Cosmetics, which eventually became the Ralph Lauren Fragrance Division of L’Oréal.

During his time as President and CEO of ZO Skin Health, Headley is given credit for being the architect of its strategy and enormous success. He conceived and launched the ZO Medical products that eventually catapulted ZO into the number one position in the medical skincare dispensing space. During his time at ZO Skin Health, sales went from $2 million annually to over $100 million in annual sales. In 2020, 51% of ZO Skin was sold to the American alternative investment management company Blackstone.

Chris Kraneiss, Chief Commercial Officer of ELEVAI Labs, also commented on the news, stating:

“We are thrilled to have Mr. Headley on the ELEVAI team. James is the perfect person to help us take ELEVAI to the next level in sales, customer service, industry recognition, and overall innovation. His expertise is invaluable to the future of ELEVAI and the growth of regenerative skincare.”

For more information, visit the ELEVAI Skincare website here.

Interested in buying ELEVAI Skincare products? Click here to find an authorized ELEVAI Skincare Professional.

View the original ELEVAI Labs press release here.

ELEVAI Labs has set the stage with its new products, and we’ll be watching as the company makes inroads into the physician-dispensed market.

Wealthy VC will be releasing an in-depth, 15-page report on ELEVAI Labs as well as interviewing the company’s CEO in the coming weeks.

Be one of the first to receive the report by Subscribing to Our Email Newsletter via the sign-up box below.

Also, please consider Following Us on Social Media via the Wealthy VC social links below to stay up to date on Elevai Labs.

Follow Wealthy VC on Social Media: Facebook | Instagram | Twitter | LinkedIn | GETTR

????Join the Discussion in the Wealthy VC Investor Group

????Have a Stock Tip or New  Story Suggestion? Email us at

Elevai Labs Inc. is a paid client of Wealthy VC.

Wealthy VC’s parent company has been compensated $13,500 per month for 12 months for investor relations, public relations, and market awareness services by Elevai Labs Inc.

This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.

View Full Disclaimer Here

Ryan Troup

Ryan Troup is the Editor in Chief of Wealthy VC and TCI. Ryan has 15+ years of investing experience. Twitter | Email

Related Articles

Back to top button